Search results
Results from the WOW.Com Content Network
Chemotherapy-induced acral erythema, also known as palmar-plantar erythrodysesthesia or hand-foot syndrome is reddening, swelling, numbness and desquamation (skin sloughing or peeling) on palms of the hands and soles of the feet (and, occasionally, on the knees, elbows, and elsewhere) that can occur after chemotherapy in patients with cancer.
As of yet, the precise etiology of necrolytic acral erythema remains unknown. Numerous causes, including hepatic dysfunction, hypoglucagonemia, hypoalbimunemia, hypoaminoacidemia, zinc deficiency, and diabetes with or without an underlying hepatitis C viral infection, have been postulated as part of the multifactorial pathophysiology of necrolytic acral erythema.
Peeling skin syndrome in the legs and feet. Peeling skin syndrome (also known as acral peeling skin syndrome, continual peeling skin syndrome, familial continual skin peeling, idiopathic deciduous skin, and keratolysis exfoliativa congenita [1]) is an autosomal recessive disorder characterized by lifelong peeling of the stratum corneum, and may be associated with pruritus, short stature, and ...
Download as PDF; Printable version; In other projects ... Generalized erythema is a skin condition that may ... Necrolytic acral erythema; List of cutaneous ...
Adverse drug reaction: palmoplantar erythrodysesthesia (acral erythema) Because circulating levels of estrogen increase in both cirrhosis and pregnancy, estrogen was thought to be the main cause for the increased vascularity. More recently, nitric oxide has also been implicated in the pathogenesis of palmar erythema. [5]
Leukotriene receptor antagonist-associated Churg–Strauss syndrome may occur in asthma patients being treated with leukotriene receptor antagonists, occurring 2 days to 10 months after the antagonist has been started, with features of the syndrome including peripheral eosinophilia, pulmonary infiltrates, and less commonly neuropathy, sinusitis, and cardiomyopathy.
Warfarin necrosis is a rare but severe complication of treatment with warfarin or related anticoagulants. [2] The typical patient appears to be an obese, middle aged woman (median age 54 years, male to female ratio 1:3). [1] [3]: 122–3 This drug eruption usually occurs between the third and tenth days of therapy with warfarin derivatives. [1]
Some of the most severe and life-threatening examples of drug eruptions are erythema multiforme, Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), hypersensitivity vasculitis, drug induced hypersensitivity syndrome (DIHS), erythroderma and acute generalized exanthematous pustulosis (AGEP). [4]